Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:T2-high asthma, classified by sputum mRNA expression of IL4, IL5, and IL13, is characterized by eosinophilia and severe phenotype
Avtorji:ID Rijavec, Matija, Klinika Golnik, Biotehniška fakulteta UL (Avtor)
ID Krumpestar, Tomaž, Klinika Golnik (Avtor)
ID Škrgat, Sabina, Klinika Golnik, Medicinska fakulteta UL, Univerzitetni klinični center Ljubljana (Avtor)
ID Kern, Izidor, Klinika Golnik (Avtor)
ID Korošec, Peter, Klinika Golnik (Avtor)
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (1,31 MB)
MD5: E6C630E451F9E0DB5B885A8A25B633A4
 
URL URL - Izvorni URL, za dostop obiščite https://www.mdpi.com/2075-1729/11/2/92/pdf
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
Povzetek:Asthma is a common chronic disease, with different underlying inflammatory mechanisms. Identification of asthma endotypes, which reflect a variable response to different treatments, is important for more precise asthma management. T2 asthma is characterized by airway inflammation driven by T2 cytokines including interleukins IL-4, IL-5, and IL-13. This study aimed to determine whether induced sputum samples can be used for gene expression profiling of T2-high asthma classified by IL4, IL5, and IL13 expression. Induced sputum samples were obtained from 44 subjects, among them 36 asthmatic patients and eight controls, and mRNA expression levels of IL4, IL5, and IL13 were quantified by RT-qPCR. Overall, gene expression levels of IL4, IL5, and IL13 were significantly increased in asthmatic patients' samples compared to controls and there was a high positive correlation between expressions of all three genes. T2 gene mean was calculated by combining the expression levels of all three genes (IL4, IL5, and IL13) and according to T2 gene mean expression in controls, we set a T2-high/T2-low cutoff value. Twenty-four (67%) asthmatic patients had T2-high endotype and those patients had significantly higher eosinophil blood and sputum counts. Furthermore, T2-high endotype was characterized as a more severe, difficult-to-treat asthma, and often uncontrolled despite the use of inhaled and/or oral corticosteroids. Therefore, the majority of those patients (15 [63%] of 24) needed adjunct biological therapy to control their asthma symptoms/exacerbations. In conclusion, we found that interleukins IL4, IL5, and IL13 transcripts could be effectively detected in sputum from asthmatic patients. Implementation of T2 gene mean can be used as sputum molecular biomarker to categorize patients into T2-high endotype, characterized by eosinophilia and severe, difficult-to-treat asthma, and often with a need for biological treatment.
Ključne besede:asthma, gene expression, interleukin-4, interleukin-5, interleukin-13, severe asthma, endotype, IL-4, IL-5, IL-13, biologic treatment
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Kraj izida:Švica
Založnik:MDPI
Leto izida:2021
Št. strani:str. 1-10
Številčenje:Vol. 1, iss. 2
PID:20.500.12556/DiRROS-13699 Novo okno
UDK:616-097
ISSN pri članku:2075-1729
DOI:10.3390/life11020092 Novo okno
COBISS.SI-ID:49321987 Novo okno
Avtorske pravice:© 2021 by the authors.
Opomba:Nasl. z nasl. zaslona; Soavtorji: Tomaž Krumpestar, Sabina Škrgat, Izidor Kern, Peter Korošec; Opis vira z dne 29. 1. 2021; Št. članka: 92;
Datum objave v DiRROS:02.02.2021
Število ogledov:1252
Število prenosov:839
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Life
Skrajšan naslov:Life
Založnik:MDPI
ISSN:2075-1729
COBISS.SI-ID:519982617 Novo okno

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:27.01.2021

Sekundarni jezik

Jezik:Ni določen
Ključne besede:astma, gensko izražanje, interlevkin-4, interlevkin-5, interlevkin-13, težka astma, endotip, IL-4, IL-5, IL-13, biološko zdravljenje


Nazaj